The main purpose of this study is to evaluate the safety and feasibility of regenerative therapy with mesenchymal stem cells from adipose tissue, administered intravenously in patients with secondary progressive multiple sclerosis who do not respond to treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
30
Intravenous infusion of autologous mesenchymal stem cells.Dose:4\*10e6 cells/Kg.
Intravenous infusion of autologous mesenchymal stem cells. Dose: 10e6 cells/Kg.
Hospital Regional Universitario de Málaga
Málaga, Málaga, Spain
Hospital Universitario Virgen Macarena
Seville, Sevilla, Spain
To evaluate safety and tolerability related to the intravenous infusion of autologous mesenchymal stem cells
Time frame: 12 months.
To evaluate effects on MS disease activity measured by: clinical variables, imaging variables, immunological and neurophysiologic analysis, neuropsychological and quality of life scales.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.